# EDGAR Filing Document

**Accession Number:** 0001980845
**File Stem:** 0001193125-26-098008
**Filing Date:** 2026-3
**Character Count:** 35511
**Document Hash:** 7c4690c9993d6e8165e89ff02c7f3ca4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-098008.hdr.sgml**: 20260309

**ACCESSION NUMBER**: 0001193125-26-098008

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260309

**DATE AS OF CHANGE**: 20260309

**EFFECTIVENESS DATE**: 20260309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** enGene Holdings Inc.
- **CENTRAL INDEX KEY:** 0001980845
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294136
- **FILM NUMBER:** 26733924

**BUSINESS ADDRESS:**
- **STREET 1:** 4868 RUE LEVY, SUITE 220
- **CITY:** SAINT-LAURENT
- **STATE:** A8
- **ZIP:** H4R 2P1
- **BUSINESS PHONE:** (514) 332-4888

**MAIL ADDRESS:**
- **STREET 1:** 4868 RUE LEVY, SUITE 220
- **CITY:** SAINT-LAURENT
- **STATE:** A8
- **ZIP:** H4R 2P1

**As filed with the Securities and Exchange Commission on March 9, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**enGene Holdings Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **British Columbia, Canada** | **Not Applicable** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**4868 Rue Levy, Suite 220**

**Saint-Laurent, QC H4R 2P1**

**Canada (514) 332-4888** 

(Address, Including Zip Code, of Principal Executive Offices)

**Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan** 

**Inducement Stock Option Awards**

(Full title of the plan)

**C T Corporation System**

**155 Federal Street**

**Suite 700**

**Boston, Massachusetts 02110**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

| | |
|:---|:---|
| **Howard A. Kenny, Esq.**<br>**Julio E. Vega, Esq.**<br>**Morgan, Lewis & Bockius LLP**<br>**101 Park Avenue**<br>**New York, New York 10178**<br>**Tel: (212) 309-6000** | **Ronald H. W. Cooper**<br>**Lee G. Giguere, Esq.**<br>**enGene Holdings Inc.**<br>**4868 Rue Levy, Suite 220**<br>**Saint-Laurent, QC H4R 2P1**<br>**Canada (514) 332-4888** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ⌧ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ⌧

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (the "Registration Statement") is being filed for the purpose of registering an additional 3,349,283 common shares, with no par value ("Common Shares"), of enGene Holdings Inc. (the "Registrant" or "enGene") reserved for issuance under the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "Plan"). The number of Common Shares reserved and available for issuance under the Plan is subject to an automatic annual increase such that the number of Common Shares authorized for issuance under the Plan increases on the first business day of each calendar year, beginning on January 1, 2026, by 5% of the aggregate number of Common Shares issued and outstanding on December 31st of the preceding calendar year (or such lesser number of Common Shares as may be determined by the compensation committee of enGene's board of directors (the "Committee")). Accordingly, on January 1, 2026, the number of Common Shares reserved and available for issuance under the Plan increased by 3,349,283 Common Shares. The additional shares are of the same class as other securities relating to the Plan, for which this Registration Statement incorporates by reference the contents of the (i) Registration Statement on Form S-8, File No. 333-277378, filed by the Registrant with the Securities and Exchange Commission (the "Commission") on February 27, 2024, and (ii) Registration Statement on Form S-8, File No. 333-285679, filed by the Registrant with the Commission on March 10, 2025, pursuant to General Instruction E to Form S-8.

This Registration Statement on Form S-8 is also filed for the purpose of registering 657,950 Common Shares issuable upon the vesting and exercise of non-qualified stock options (the "Inducement Awards") under previously announced inducement stock option awards granted on September 30, 2025. The Inducement Awards were issued by the Registrant to certain individuals as an inducement material to each such individual's employment with the Registrant and were approved by the compensation committee of the Registrant's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4).

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The documents containing the information required in Part I of this Registration Statement have been or will be sent or given to (i) the participating employees included in the Plan covered by this Registration Statement and (ii) the employees issued the Inducement Awards, in each case as specified in Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act"), in accordance with the rules and regulations of the Commission. Such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the Registrant with the Commission are hereby incorporated by reference in this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)The Registrant's [<u>Annual Report on Form 10-K for the fiscal year ended October 31, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001980845/000119312525328743/engn-20251031.htm) filed with the Commission on December 22, 2025, as amended by [<u>Amendment No. 1 to our Annual Report on Form 10-K/A for the year ended October 31, 2025 filed with the Commission on February 19, 2026</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001980845/000119312526059409/engn-20251031.htm);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)The Registrant's Quarterly Report on [<u>Form 10-Q for the quarter ended January 31, 2026,</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001980845/000119312526097541/engn-20260131.htm) filed with the Commission on March 9, 2026;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)The Registrant's Current Reports on Form 8-K, filed with the Commission on [<u>November 12, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001980845/000119312525275722/d28722d8k.htm), [<u>November 14, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001980845/000119312525283182/d876714d8k.htm), [<u>January 21, 2026</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001980845/000119312526017945/engn-20260120.htm) and [<u>March 9, 2026</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001980845/000119312526097546/engn-20260309.htm) (excluding any portions thereof that are furnished and not filed); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)The description of the Registrant's securities contained in [<u>Exhibit 4.6 to the Registrant's</u> <u>Annual Report on Form 10-K for the year ended October 31, 2023, filed with the Commission on January 29, 2024</u>](https://www.sec.gov/Archives/edgar/data/1980845/000095017024008125/engn-ex4_6.htm), including any amendments or reports filed for the purpose of updating such description.

All other reports and documents subsequently filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement (in each case excluding any information furnished and not filed according to applicable rules, such as information furnished pursuant to Item 2.02 or Item 7.01 on any Current Report on Form 8-K) and to be part hereof from the date of filing of such reports and documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 4. Description of Securities.** 

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

enGene is governed by the Business Corporations Act (British Columbia) (the "BCBCA"). Under the BCBCA, and our articles (the "Articles"), enGene may (or must, pursuant to the Articles) indemnify all eligible parties against all eligible penalties to which such person is or may be liable, and we must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. Each director of enGene is deemed to have contracted with enGene on the terms of indemnity contained in the Articles.

For the purposes of such an indemnification:

"eligible party" means an individual who

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•is or was a director or officer of enGene;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•is or was a director or officer of another corporation

oat a time when the corporation is or was an affiliate of enGene, or

oat the request of enGene; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•at the request of enGene, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity and includes the heirs and personal or other legal representatives of that individual;

"eligible penalty" means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding;

------

"eligible proceeding" means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, enGene or an associated corporation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•is or may be joined as a party, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding;

"expenses" includes costs, charges and expenses, including legal and other fees, but does not include judgments, penalties, fines or amounts paid in settlement of a proceeding; and

"proceeding" includes any legal proceeding or investigative action, whether current, threatened, pending or completed.

In addition, under the BCBCA, enGene may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, provided that enGene first receives from the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited by the restrictions noted below, the eligible party will repay the amounts advanced.

Notwithstanding the provisions of enGene's Articles noted above, enGene must not indemnify an eligible party or pay the expenses of an eligible party, if any of the following circumstances apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses was made, enGene was prohibited from giving the indemnity or paying the expenses by its articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, enGene is prohibited from giving the indemnity or paying the expenses by its articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of enGene or the associated corporation, as the case may be; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party's conduct in respect of which the proceeding was brought was lawful.

In addition, if an eligible proceeding is brought against an eligible party by or on behalf of enGene or by or on behalf of an associated corporation, enGene must not do either of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•indemnify the eligible party in respect of the proceeding; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•pay the expenses of the eligible party in respect of the proceeding.

Notwithstanding any of the foregoing, and whether or not payment of expenses or indemnification has been sought, authorized or declined under the BCBCA or the Articles of enGene, on the application of enGene or an eligible party, the Supreme Court of British Columbia may do one or more of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•order enGene to indemnify an eligible party against any liability incurred by the eligible party in respect of an eligible proceeding;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• order enGene to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• order the enforcement of, or any payment under, an agreement of indemnification entered into by enGene;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• order enGene to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order under this section; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• make any other order the court considers appropriate.

The BCBCA and enGene's Articles authorize us to purchase and maintain insurance for the benefit of an eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, enGene, a current or former affiliate of enGene or a corporation, partnership, trust, joint venture or other unincorporated entity at the request of enGene.

In addition, enGene has entered, or will enter, into separate indemnity agreements with each of its directors and officers pursuant to which enGene has or will agree to indemnify and hold harmless its directors and officers against any and all liability, loss, damage, cost or expense in accordance with the terms and conditions of the BCBCA and the Articles.

 **Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit<br>Number** | &nbsp;&nbsp;**Description** |
| &nbsp;&nbsp;4.1 | &nbsp;&nbsp;[<u>Articles of enGene Holdings Inc. (incorporated by reference to Exhibit 3.1 to enGene's Form S-4/A Registration Statement Registration No.: 333-273851 filed with the Commission on September 26, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1) |
| &nbsp;&nbsp;4.2 | &nbsp;&nbsp;[<u>Specimen Common Share Certificate of enGene (incorporated by reference to Exhibit 4.1 to enGene's Form S-4/A Registration Statement Registration No.: 333-273851 filed with the Commission on</u>](https://www.sec.gov/Archives/edgar/data/1980845/000119312523224097/d459793dex41.htm)<br>[<u>September 26, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1980845/000119312523224097/d459793dex41.htm) |
| &nbsp;&nbsp;4.3 | &nbsp;&nbsp;[<u>Specimen Warrant Certificate of enGene (incorporated by reference to Exhibit 4.3 to enGene's Form S-4/A Registration Statement Registration No.: 333-273851 filed with the Commission on September 26, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_5) |
| &nbsp;&nbsp;4.4 | &nbsp;&nbsp;[<u>enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated herein by reference to Exhibit 10.20 of enGene's Current Report on Form 8-K filed with the SEC on October 31, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1020.htm) |
| &nbsp;&nbsp;4.5 | &nbsp;&nbsp;[<u>Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated by reference to Exhibit 10.1 of enGene's Current Report on Form 8-K filed with the SEC on May 15, 2024).</u>](https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/engn-ex10_1.htm) |
| &nbsp;&nbsp;5.1 | &nbsp;&nbsp;[<u>Opinion of Blake, Cassels & Graydon LLP\*</u>](engn-ex5_1.htm) |
| &nbsp;&nbsp;23.1 | &nbsp;&nbsp;[<u>Consent of KPMG LLP\*</u>](engn-ex23_1.htm) |
| &nbsp;&nbsp;23.2 | &nbsp;&nbsp;[<u>Consent of Blake, Cassels & Graydon LLP (included in Exhibit 5.1 hereto)\*</u>](engn-ex5_1.htm) |
| &nbsp;&nbsp;24.1 | &nbsp;&nbsp;[<u>Power of Attorney (included on the signature page hereto)\*</u>](#power_of_attorney) |
| &nbsp;&nbsp;107 | &nbsp;&nbsp;[<u>Filing Fee Table\*</u>](engn_exfilingfees.htm) |

---

\* Filed herewith.

**Item 9. Undertakings.**

(a) The undersigned registrant hereby undertakes:

------

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Table" in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

*Provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) That, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**Signatures**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Saint-Laurent, Quebec, Canada, on the 9th day of March, 2026.

---

| | |
|:---|:---|
| **enGene Holdings Inc.** | **enGene Holdings Inc.** |
| By: | /s/ Ronald H.W. Cooper |
|  | Name: Ronald H. W. Cooper |
|  | Title: Chief Executive Officer and President |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints each of Ronald H. W. Cooper, Ryan Daws, and Lee Giguere, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement (and any additional registration statement related hereto permitted by Rule 462(b) promulgated under the Securities Act (and all further amendments, including post-effective amendments, thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Signature** | &nbsp;&nbsp;**Title** | &nbsp;&nbsp;**Date** |
| &nbsp;&nbsp; <br>/s/ Ronald H.W. Cooper | &nbsp;&nbsp;Chief Executive Officer, President and Director<br>(*Principal Executive Officer*) | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Ronald H. W. Cooper |  |  |
| &nbsp;&nbsp; <br>/s/ Ryan Daws | &nbsp;&nbsp;Chief Financial Officer <br>(*Principal Financial Officer and Principal Accounting Officer*) | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Ryan Daws<br>|  |  |
| &nbsp;&nbsp; <br>/s/ Philip Astley-Sparke | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Philip Astley-Sparke |  |  |

---

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; <br>/s/ Gerald Brunk | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Gerald Brunk |  |  |
| &nbsp;&nbsp; <br>/s/ Dr. Richard Glickman | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Dr. Richard Glickman |  |  |
| &nbsp;&nbsp; <br>/s/ Dr. William Grossman | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Dr. William Grossman |  |  |
| &nbsp;&nbsp; <br>/s/ Paul Hastings | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Paul Hastings |  |  |
| &nbsp;&nbsp; <br>/s/ Michael Heffernan | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Michael Heffernan |  |  |
| &nbsp;&nbsp; <br>/s/ Wouter Joustra | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Wouter Joustra |  |  |
| &nbsp;&nbsp; <br>/s/ Lota Zoth | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 9, 2026 |
| &nbsp;&nbsp;Lota Zoth |  |  |

---

------

## Exhibit 5.1

Exhibit 5.1

---

| | |
|:---|:---|
| &nbsp;&nbsp;![img93391562_0.jpg](img93391562_0.jpg) | &nbsp;&nbsp;![img93391562_1.jpg](img93391562_1.jpg) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;March 9, 2026 |  |
|  | &nbsp;&nbsp;Reference: 99472/4 |
| &nbsp;&nbsp;enGene Holdings Inc.<br>Suite 220, 4868 Rue Levy,<br>Saint-Laurent, Quebec<br>Canada H4R 2P1 |  |
| &nbsp;&nbsp;enGene Holdings Inc.<br>Suite 220, 4868 Rue Levy,<br>Saint-Laurent, Quebec<br>Canada H4R 2P1 | &nbsp;&nbsp; <br>|

---

**RE: enGene Holdings Inc. – Registration Statement on Form S-8**

Dear Sirs/Mesdames:

We have acted as Canadian counsel for enGene Holdings Inc. (the "**Company**"), a company existing under the laws of the Province of British Columbia, in connection with the filing by the Company with the Securities and Exchange Commission (the "**Commission**") of a registration statement on Form S-8 (such registration statement, as it may be amended from time to time, is referred to herein as the "**Registration Statement**") relating to the registration pursuant to the United States *Securities Act of 1933*, as amended (the "**Securities Act**"), of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)3,349,283 common shares in the capital of the Company (the "**Incentive Awards Shares**") which are reserved for issuance pursuant to the exercise or settlement, as applicable, of incentive stock options, nonqualified stock options, stock appreciation rights, share awards, share units and other share-based awards (collectively, the "**Incentive Awards**") which may be granted under the Company's Amended and Restated 2023 Incentive Equity Plan (the "**Incentive Plan**"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)657,950 common shares in the capital of the Company (the "**Inducement Awards Shares**", and together with the Incentive Awards Shares, the "**Shares**") which are reserved for issuance pursuant to the exercise of nonqualified stock options granted as inducement awards on September 30, 2025 (collectively the "**Inducement Awards**", and together with the Incentive Awards, the "**Awards**").

For the purposes of this opinion we have reviewed such corporate records of the Company and other documents as we have deemed necessary or desirable to give the opinion expressed below.

We have assumed the genuineness of all signatures, the legal capacity of all individuals and the authenticity of all documents submitted to us as originals, the conformity to authentic original documents of all documents submitted to us as certified, conformed or photostatic copies or facsimiles thereof, and the completeness and accuracy of the corporate records in our possession as of the date hereof.

Based upon and subject to the foregoing, and provided that all necessary corporate action has been taken by the Company to authorize the issuance of the Awards, we are of the opinion that:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)upon the due exercise or settlement, as applicable, of the Incentive Awards in accordance with their terms and the terms of the Incentive Plan, the Incentive Awards Shares underlying the Incentive Awards will be validly issued as fully paid and non-assessable common shares in the capital of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)upon the due exercise of the Inducement Awards in accordance with their terms, the Inducement Awards Shares underlying the Inducement Awards will be validly issued as fully paid and non-assessable common shares in the capital of the Company

The opinions expressed in this letter are subject to the following exceptions and qualifications:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)we do not express any opinion with respect to the laws of any jurisdiction other than British Columbia and the federal laws of Canada specifically applicable therein; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)our opinion is based on legislation and regulations in effect on the date hereof.

Consent is hereby given to the use of our name in the Registration Statement and to the filing, as an exhibit to the Registration Statement, of this opinion. In giving such consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act, and the rules and regulations thereunder.

Yours very truly,

/s/ Blake, Cassels & Graydon LLP

------

## Exhibit 23.1

## Consent of Independent Registered Public Accounting Firm

## We consent to the use of our report dated December 22, 2025, with respect to the consolidated balance sheets as of October 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, shareholders' equity and cash flows for the years then ended, and the related notes, of enGene Holdings Inc. incorporated herein by reference.

## /s/ KPMG LLP

## March 9, 2026

## Montréal, Canada

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107** 

**Calculation of Filing** Fee **Tables**

**Form** S-8

(Form Type)

enGene Holdings Inc.

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered (1)** | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Shares, no par value per share | Rule 457(c) and Rule 457(h) | 3349283 (2) | $9.63 (3) | $32253595.29 (3) | 0.00013810 | $4454.22 |
| Equity | Common Shares, no par value per share | Rule 457(h) | 657950 (4) | $6.83 (5) | $4493798.50 (5) | 0.00013810 | $620.59 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  | $36747393.79 |  | $5074.81 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $5074.81 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional common shares, without par value (the "Common Shares") that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction.

(2) Consists of 3,349,283 additional Common Shares issuable under the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "Plan"), which represents the automatic annual increase to the number of shares available for issuance under the Plan as of January 1, 2026.

(3) Estimated in accordance with Rule 457(c) and Rule 457(h) promulgated under the Securities Act solely for the purpose of calculating the registration fee based on the average of the high and low prices of the Common Shares as reported on the Nasdaq Capital Market on March 3, 2026.

(4) Represents the maximum number of Common Shares issuable pursuant to the inducement stock option awards made pursuant to and in accordance with the inducement grant exception under Nasdaq Listing Rule 5635(c)(4).

(5) Estimated in accordance with Rule 457(h) promulgated under the Securities Act solely for the purpose of calculating the registration fee based upon the exercise price of the inducement options.

------